Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis
about
Epidemiology of meningitis in an HIV-infected Ugandan cohortHost immunity to Cryptococcus neoformansPreventing Cryptococcosis-Shifting the Paradigm in the Era of Highly Active Antiretroviral TherapyHIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited SettingsCryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness AnalysisNovel cell-based in vitro screen to identify small-molecule inhibitors against intracellular replication of Cryptococcus neoformans in macrophagesCryptococcal meningitis: epidemiology and therapeutic options.Performance of cryptococcal antigen lateral flow assay using saliva in Ugandans with CD4 <100.Cost-effective diagnostic checklists for meningitis in resource-limited settings.Long term 5-year survival of persons with cryptococcal meningitis or asymptomatic subclinical antigenemia in Uganda.Methods of rapid diagnosis for the etiology of meningitis in adultsStandardized electrolyte supplementation and fluid management improves survival during amphotericin therapy for cryptococcal meningitis in resource-limited settings.Accuracy of noninvasive intraocular pressure or optic nerve sheath diameter measurements for predicting elevated intracranial pressure in cryptococcal meningitis.Comparative effectiveness of induction therapy for human immunodeficiency virus-associated cryptococcal meningitis: a network meta-analysis.Potential Cost-Effectiveness of Prenatal Distribution of Misoprostol for Prevention of Postpartum Hemorrhage in Uganda.Cryptococcal Antigenemia in Immunocompromised Human Immunodeficiency Virus Patients in Rural Tanzania: A Preventable Cause of Early Mortality.Cryptococcal Meningitis: Diagnosis and Management Update.Screening HIV-Infected Patients with Low CD4 Counts for Cryptococcal Antigenemia prior to Initiation of Antiretroviral Therapy: Cost Effectiveness of Alternative Screening Strategies in South AfricaIncreased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda.Cost-effectiveness of CRAG-LFA screening for cryptococcal meningitis among people living with HIV in Uganda.Reproducibility of CSF quantitative culture methods for estimating rate of clearance in cryptococcal meningitisNew Insights into HIV/AIDS-Associated Cryptococcosis.Comparison of cryptococcal antigenemia between antiretroviral naïve and antiretroviral experienced HIV positive patients at two hospitals in Ethiopia.Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realizedRecent advances in AIDS-related cryptococcal meningitis treatment with an emphasis on resource limited settings.Use of Fungal Diagnostics and Therapy in Pediatric Cancer Patients in Resource-Limited Settings.Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis.Voriconazole combined with low-dose amphotericin B liposome for treatment of cryptococcal meningitis.Short-Course Induction Treatment with Intrathecal Amphotericin B Lipid Emulsion for HIV Infected Patients with Cryptococcal Meningitis.Curcumin enhances the activity of fluconazole against Cryptococcus gattii-induced cryptococcosis infection in mice.Neuroimaging of HIV-associated cryptococcal meningitis: comparison of magnetic resonance imaging findings in patients with and without immune reconstitution.Inadequacy of High-Dose Fluconazole Monotherapy Among Cerebrospinal Fluid Cryptococcal Antigen (CrAg)-Positive Human Immunodeficiency Virus-Infected Persons in an Ethiopian CrAg Screening Program.Evaluation of antifungal combination against Cryptococcus spp.HIV-Associated Cryptococcal Disease in Resource-Limited Settings: A Case for "Prevention Is Better Than Cure"?
P2860
Q24273288-A1B11E1D-8D75-41CF-8392-AE6529F00C35Q26823438-0E4C0980-D2E6-4995-B375-CBDAF3212539Q26994750-35E9D9AF-1CF9-4C4B-A339-6A0DEA9B7A08Q28078958-07393C35-08C2-465B-86A6-CE006EC9EFFBQ28274334-C7CB9956-BEFD-4304-9D39-BBF0BF1906F3Q28830321-8F655B53-7224-4E7E-89C8-2F67B9A3A468Q33633343-8552AC37-B2C8-4583-ADD7-902EF0DA22DBQ33982206-5F50B2D7-222D-4B00-BAB4-AEB3E6EF771EQ34331360-A41211A3-F469-43FD-958F-CEEF734CAD6DQ34516367-55D4B3F6-1835-4D29-9DD3-533C899DA058Q34554521-859BE188-B8B2-4CDF-91E4-DDC42BCDD338Q34801921-C4062AC6-8323-4426-82D0-2969C8710F7EQ35072051-5CB412C5-F787-43CB-AFD7-DE4A051177A0Q35628245-5CF913E0-403D-44EE-9652-25B977A074A4Q35839057-28F77416-41B9-4A9F-9F0A-A401FBE38FD5Q35880502-325A2C1B-C3C0-4951-A7FD-BA8B08B56F1CQ35951094-A4F73409-BF2A-45EB-BD8C-D261802800A7Q36070803-1E6627FE-0C5D-4C0E-92E0-E9CA85D76E75Q36290696-E05F7B3D-D78F-4AA3-B81C-1E9C91E0CC0DQ36321037-8FB6B1C1-4877-408C-A513-7ED429D32BC6Q36807382-2434ECC1-D4D3-42F1-B3F7-D2737E49C2E8Q37156556-2D8DE43F-40C5-482A-BE44-54EE79FFA502Q37215923-527E8AFD-77A4-474D-8F8F-17978B4E0289Q37393668-C0F5F5F0-875B-4356-87A6-3D2216D88F72Q38851467-058006E5-BEE3-405F-871C-877098464624Q38965488-1FFC2FE0-7728-4A8E-938C-1ABB4BF4EB71Q39379643-B33854FF-0A87-4709-AB31-9962828C6652Q40728787-A5071168-E9C3-418A-91BC-8E79E9B2D9F5Q40961271-081197D8-02FF-4AF7-B062-79DE60B27B3DQ40963460-AF8BF73B-E929-401B-A9C6-59236E306071Q41400251-A55F94B2-9134-490F-8760-46025F6AA5E0Q45326483-7A184434-A904-4A9C-B933-6C4F1DD242DEQ46554956-B8667A63-412C-4277-9C13-D4E2F7486540Q47646979-B1685B99-82BC-4FB7-A2BD-1D1A87446430
P2860
Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Cryptococcal meningitis treatm ...... a cost-effectiveness analysis
@ast
Cryptococcal meningitis treatm ...... a cost-effectiveness analysis
@en
Cryptococcal meningitis treatm ...... a cost-effectiveness analysis
@en-gb
Cryptococcal meningitis treatm ...... a cost-effectiveness analysis
@nl
type
label
Cryptococcal meningitis treatm ...... a cost-effectiveness analysis
@ast
Cryptococcal meningitis treatm ...... a cost-effectiveness analysis
@en
Cryptococcal meningitis treatm ...... a cost-effectiveness analysis
@en-gb
Cryptococcal meningitis treatm ...... a cost-effectiveness analysis
@nl
altLabel
Cryptococcal Meningitis Treatm ...... A Cost-Effectiveness Analysis
@en
prefLabel
Cryptococcal meningitis treatm ...... a cost-effectiveness analysis
@ast
Cryptococcal meningitis treatm ...... a cost-effectiveness analysis
@en
Cryptococcal meningitis treatm ...... a cost-effectiveness analysis
@en-gb
Cryptococcal meningitis treatm ...... a cost-effectiveness analysis
@nl
P2093
P2860
P3181
P1433
P1476
Cryptococcal meningitis treatm ...... a cost-effectiveness analysis
@en
P2093
Kate E Birkenkamp
Melissa A Rolfes
Radha Rajasingham
P2860
P304
P3181
P356
10.1371/JOURNAL.PMED.1001316
P407
P577
2012-01-01T00:00:00Z